Humana Inc. (HUM) is one of the most debated names in managed care, and its analyst price targets reflect that divide. Recent individual targets include $596 at Robert W. Baird, $582 at Barclays, $525 at Oppenheimer, $520 at Raymond James, $495 at both Mizuho and UBS, $480 at Evercore ISI, $475 at Truist, $471 at Guggenheim, and $460 at Cantor Fitzgerald. The low end of the current range sits near $280, producing an unusually wide $280-to-$596 spread.
Averaging the roughly two dozen current targets yields a figure near $465, the rounded central target used here. That is consistent with independent aggregations — S&P Global's 26-analyst average of about $465 and Barron's figure near $460 — though it should not be read as a guarantee. Analysts cluster around a "Buy" stance, but the gap between the cautious and bullish camps is driven by differing assumptions about how quickly Medicare Advantage margins recover and whether the valuation premium can be sustained.
Humana closed near $414.50 on October 30, 2026, toward the upper end of a 52-week range of $163.11 to $456.50 after a powerful run. Moving to $465 requires about 12% upside — a modest advance by equity standards but one that would take the stock above its prior high and into new territory.
The path hinges on execution rather than multiple expansion alone. Humana trades at a forward P/E (price-to-earnings ratio) well above large managed-care peers, so further gains would most plausibly come from evidence that its multiyear Medicare Advantage margin-restoration plan — targeting at least a 3% pretax margin by 2028 — is tracking ahead of schedule, alongside continued Star Ratings momentum and cost discipline in its CenterWell care-delivery segment.
Humana's 52-week high of $456.50, set in early October, is the most important resistance level between the current price and the $465 target — a decisive break above it would be a notable technical signal. Below the market, the recent pullback found support in the $409-to-$411 zone, with the psychologically important $400 level the next area of interest. The long-term structure is constructive after a rebound from the $163 low, but the sharp year-to-date advance leaves the stock vulnerable to profit-taking at new highs.
Analyst price targets typically reflect a roughly 12-month research horizon, though individual assumptions vary widely given the divergence in the $280-to-$596 range. The most consequential near-term events are the November 6, 2026 third-quarter earnings release and any update to full-year guidance; the Centers for Medicare & Medicaid Services rate and Stars developments; medical cost trend data; analyst estimate revisions; and progress on the CenterWell joint venture and the Medicare Advantage membership transition. No specific timing for reaching $465 should be assumed.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile, sentiment-sensitive name like Humana, the tool can help traders surface emerging opportunities, track existing positions, and identify shifting trends more efficiently than manual review. Traders can explore the signals to complement their own research on HUM and the broader managed-care sector.
The $465 central target — the average of current analyst price targets spanning roughly $280 to $596 — implies a modest 12% move from the latest close near $414.50. The bull case rests on a genuine Star Ratings turnaround, reinstated bonus revenue, and a credible multiyear margin plan, reinforced by a recent run of upgrades. The bear case emphasizes an elevated valuation, execution uncertainty, and regulatory exposure. Given the unusually wide analyst dispersion, investors should treat $465 as a midpoint of informed opinion rather than a precise forecast, and watch the November earnings report and margin trends as the key tests of the thesis.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, HUM has been closely correlated with UNH. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if HUM jumps, then UNH could also see price increases.